Creative Planning’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-19,322
| Closed | -$2.55M | – | 3823 |
|
|
2025
Q1 | $2.55M | Buy |
19,322
+1,420
| +8% | +$177K | ﹤0.01% | 1026 |
|
|
2024
Q4 | $1.5M | Buy |
17,902
+1,714
| +11% | +$141K | ﹤0.01% | 1332 |
|
|
2024
Q3 | $1.18M | Sell |
16,188
-3,423
| -17% | -$257K | ﹤0.01% | 1397 |
|
|
2024
Q2 | $1.34M | Buy |
19,611
+6,172
| +46% | +$428K | ﹤0.01% | 1213 |
|
|
2024
Q1 | $930K | Buy |
13,439
+2,549
| +23% | +$175K | ﹤0.01% | 1378 |
|
|
2023
Q4 | $780K | Buy |
10,890
+5,136
| +89% | +$295K | ﹤0.01% | 1388 |
|
|
2023
Q3 | $300K | Buy |
5,754
+1,373
| +31% | +$80K | ﹤0.01% | 1947 |
|
|
2023
Q2 | $277K | Buy |
+4,381
| New | +$273K | ﹤0.01% | 1961 |
|
|
2020
Q1 | – | Sell |
-9,300
| Closed | -$319K | – | 2119 |
|
|
2019
Q4 | $319K | Buy |
+9,300
| New | +$112K | ﹤0.01% | 1370 |
|
|
2019
Q3 | – | Sell |
-20,425
| Closed | -$265K | – | 2129 |
|
|
2019
Q2 | $265K | Hold |
20,425
| – | – | ﹤0.01% | 1448 |
|
|
2019
Q1 | $249K | Buy |
20,425
+425
| +2% | +$5.43K | ﹤0.01% | 1447 |
|
|
2018
Q4 | $228K | Buy |
+20,000
| New | +$323K | ﹤0.01% | 1402 |
|
|
2017
Q3 | – | Sell |
-900
| Closed | -$11K | – | 3812 |
|
|
2017
Q2 | $11K | Hold |
900
| – | – | ﹤0.01% | 3589 |
|
|
2017
Q1 | $15K | Buy |
900
+845
| +1,536% | +$12.2K | ﹤0.01% | 3349 |
|
|
2016
Q4 | $1K | Sell |
55
-75
| -58% | -$1.06K | ﹤0.01% | 4516 |
|
|
2016
Q3 | $2K | Buy |
+130
| New | +$5.26K | ﹤0.01% | 4274 |
|
Other funds holding ITCI
Creative Planning's ITCI Position: Q2 2025 in Review
Creative Planning sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 19,322 shares — an estimated $2.55M sold.
Creative Planning first reported a position in ITCI in Q3 2016 and held it in 16 quarters. The position peaked at $2.55M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Creative Planning reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Creative Planning sold 19,322 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.55M.
- Creative Planning first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 16 quarters.
- Creative Planning's Intra-Cellular Therapies Inc. position peaked at $2.55M in Q1 2025.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Creative Planning's 13F filing for Q2 2025, filed 8 Aug 2025.